Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 139 in Healthy Subjects and Subjects with Moderate to Severe Psoriasis

Trial Identifier: 20080767
Sponsor: AstraZeneca
NCTID:: NCT01094093
Start Date: April 2010
Primary Completion Date: July 2011
Condition: Psoriasis

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Australia Adelaide, Australia, SA500
Australia Herston, Australia, 4006
Australia, Victoria Melbourne, Victoria, Australia, 3004
New Zealand Grafton, New Zealand, 1010